Collection of Bioactive Reference Compounds for Focused Library Design

QSAR and Combinatorial Science

Volumn 22, Issue 7, 2003, Pages 713-718

  Schneider, Petra ^a,c   Schneider, Gisbert ^b  

^a Schneider Consulting GbR   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c NONE   (Germany)

Author keywords

Combinatorial design; Drug likeness; Pharmacophore; Self organizing map; Similarity

Indexed keywords

CONFORMAL MAPPING; DATA VISUALIZATION; DIGITAL LIBRARIES; MOLECULAR WEIGHT DISTRIBUTION; MOLECULES;

BIOACTIVES; COMBINATORIAL DESIGN; DRUG CANDIDATES; DRUG-LIKENESS; LIBRARY DESIGNS; PHARMACOPHORES; REFERENCE COMPOUNDS; SCIENTIFIC LITERATURE; SELF-ORGANIZING-MAPS; SIMILARITY;

SELF ORGANIZING MAPS;

ARTICLE; COMBINATORIAL LIBRARY; INFORMATION PROCESSING; LIPOPHILICITY; MOLECULAR WEIGHT; PHARMACOPHORE; PRIORITY JOURNAL; SCIENTIFIC LITERATURE;

EID: 0242467732     PISSN: 1611020X     EISSN: None     Source Type: Journal    
DOI: 10.1002/qsar.200330825     Document Type: Article

References (41)

1. G. Schneider, H.-J. Böhm, Virtual screening and fast automated docking methods, Drug Discov. Today 2002, 7, 64-70.
2. T. Langer, R. D. Hoffmann, Virtual screening: an effective tool for lead structure discovery? Curr. Pharm. Des. 2001, 7, 509-527.
3. O. F. Guner, History and evolution of the pharmacophore concept in computer-aided drug design, Curr. Top. Med. Chem. 2002, 2, 1321-1332.
4. T. Klabunde, G. Hessler, Drug design strategies for targeting G-protein-coupled receptors, Chembiochem 2002, 3, 928-944.
5. A. Tropsha, W. Zheng, Identification of the descriptor pharmacophores using variable selection QSAR: applications to database mining, Curr. Pharm. Des. 2001, 7, 599-612.
6. H.-J. Böhm, G. Schneider (Eds.), Virtual screening for bioactive molecules, Wiley-VCH, Weinheim, 2000
7. M. Otto, Chemometrics - Statistics and computer application in analytical chemistry, Wiley-VCH, Weinheim, 1999.
8. A. K. Ghose, V. N. Viswanadhan (Eds.), Combinatorial library design and evaluation - Principles, software tools, and applications in drug discovery, Marcel Dekker, New York, Basel, 2001.
9. nd edition, Churchill Livingstone, Edinburgh, 1999.
10. W. Forth, D. Henschler, W. Rummel, Allgemeine und spezielle Pharmakologie und Toxikologie, Urban & Fischer, München, 2001.
11. E. Mutschler, G. Geisslinger, H. K. Kroemer, M. Schäfer-Korting, Arzneimittelwirkungen - Lehrbuch der Pharmakologie und Toxikologie, Wissenschaftliche Verlagsgesellschaft mbH, Stuttgart, 2001.
12. G. Schneider, W. Neidhart, T. Giller, G. Schmid, " Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening, Angew. Chem. Int. Ed. Engl. 1999, 38, 2894-2896.
13. R. E. Carhart, D. H. Smith, R. Venkataraghavan, Atom pairs as molecular features in structure-activity studies: definition and applications, J. Chem. Inf. Comput. Sci. 1985, 25, 64-73.
14. G. Moreau, P. Broto, The autocorrelation of a topological structure: a new molecular descriptor Nouv. J. Chim. 1980, 4, 359-360; G. Moreau, P. Broto, Autocorrelation of molecular structures: Application to SAR studies, ibid. 757-764.
15. G. Moreau, P. Broto, The autocorrelation of a topological structure: a new molecular descriptor Nouv. J. Chim. 1980, 4, 359-360; G. Moreau, P. Broto, Autocorrelation of molecular structures: Application to SAR studies, ibid. 757-764.
16. T. Kohonen, Self-organized formation of topologically correct feature maps, Biol. Cybern. 1982, 43, 59-69.
17. nd edition, Wiley-VCH, Weinheim, 1999.
18. J. Devillers (Ed.), Neural networks in QSAR and drug design, Academic Press, New York, 1996.
19. T. Kohonen, Self-organizing maps, Springer Series in Information Sciences, Vol. 30, Springer, Berlin, 2001.
20. G. Scapin, Structural biology in drug design: selective protein kinase inhibitors, Drug Discov. Today 2002, 7, 601-611.
21. J. R. Woolfrey, G. S. Weston, The use of computational methods in the discovery and design of kinase inhibitors, Curr. Pharm. Des. 2002, 8, 1527-1545.
22. J. Drews, S. Ryser (Eds.), Human disease - from genetic causes to biochemical effects, Ex Libris Roche, Basel, 1997.
23. C. A. Lipinski, F. Lombardo, B. W. Dominy, P. J. Feeney, Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 2001, 46, 3-26.
24. A. K. Ghose, V. N. Viswanadhan, J. J. Wendoloski, A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases, J. Comb. Chem. 1999, 1, 55-68.
25. Ajay, Predicting drug-likeness: why and how? Curr. Top. Med. Chem. 2002, 2, 1273-1286.
26. W. P. Walters, M. A. Murcko, Prediction of "drug-likeness", Adv. Drug Deliv. Rev. 2002, 54, 255-271.
27. W. J. Egan, W. P. Walters, M. A. Murcko, Guiding molecules towards drug-likeness, Curr. Opin. Drug Discov. Devel. 2002, 5, 540-549.
28. C. A. Lipinski, Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Meth. 2000, 44, 235-249.
29. T. I. Oprea, Current trends in lead discovery: are we looking for the appropriate properties? J. Comput. Aided Mol. Des. 2002, 16, 325-334.
30. V. Dive, J. Cotton, A. Yiotakis, A. Michaud, S. Vassiliou, J. Jiracek, G. Vazeux, M. T. Chauvet, P. Cuniasse, P. Corvol, RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites, Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 4330-4335.
31. G. Schneider, So, S.-S., Adaptive systems in drug design, Landes Bioscience, Georgetown, 2001.
32. M. Nettekoven, G. Schneider, Ligand-based combinatorial design of selective purinergic receptor (A(2A)) antagonists using self-organizing maps, J. Comb. Chem. 2003, 5, 233-237.
33. M. Böhm, J. Stürzebecher, G. Klebe, Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa, J. Med. Chem. 1999, 42, 458-477.
34. M. Renatus, W. Bode, R. Huber, J. Stürzebecher, M. T. Stubbs, Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase, J. Med. Chem. 1998, 41, 5445-5456.
35. C. Eigenbrot, Structure, function, and activation of coagulation factor VII, Curr. Protein Pept. Sci. 2002, 3, 287-299.
36. R. Rai, P. A. Sprengeler, K. C. Elrod, W. B. Young, Perspectives on factor Xa inhibition, Curr. Med. Chem. 2001, 8, 101-119.
37. H. Van Aken, C. Bode, H. Darius, C. Diehm, A. Encke, D. C. Gulba, S. Haas, W. Hacke, W. Puhl, M. Quante, H. Riess, R. Scharf, S. Schellong, T. Schror, K. L. Schulte, U. Tebbe, Anticoagulation: the present and future, Clin. Appl. Thromb. Hemost. 2001, 7, 195-204.
38. T. Naumann, H. Matter, Structural classification of protein kinases using 3D molecular interaction field analysis of their ligand binding sites: target family landscapes, J. Med. Chem. 2002, 45, 2366-2378.
39. A. Schuffenhauer, J. Zimmermann, R. Stoop, J. J. van der Vyver, S. Lecchini, E. Jacoby, An ontology for pharmaceutical ligands and its application for in silico screening and library design, J. Chem. Inf. Comput. Sci. 2002, 42, 947-955.
40. K. H. Bleicher, Chemogenomics: bridging a drug discovery gap, Curr. Med. Chem. 2002, 9, 2077-2084.
41. H. Kubinyi, The design of combinatorial libraries, Drug Discov. Today 2002, 7, 503-504.